🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT07557056Phase 21 site📍 Columbus Jennifer Woyach · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Nemtabrutinib Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites📍 Chandler📍 Duarte📍 Irvine Loxo Oncology, Inc. · Tests: Pirtobrutinib The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Los Angeles AVM Biotechnology Inc · Tests: AVM0703 Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) NCT07509151Phase 344 sites📍 La Jolla📍 Denver📍 New Haven AstraZeneca · Tests: Surovatamig A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038Phase 1, Phase 265 sites📍 Boston📍 Hackensack📍 New Brunswick AstraZeneca · Tests: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia NCT05336812Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Acalabrutinib, Obinutuzumab, Venetoclax Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902Phase 3632 sites📍 Birmingham📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab NCT07024706Phase 247 sites📍 Boston📍 Charlotte📍 Charlotte AstraZeneca · Tests: Acalabrutinib, Venetoclax Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial NCT04941716Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL NCT05963217Phase 11 site📍 Toronto University Health Network, Toronto · Tests: TBI-2001, Cyclophosphamide, Fludarabine A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187Phase 3217 sites📍 Birmingham📍 Phoenix📍 Irvine BeOne Medicines · Tests: Tacabrutideg, Pirtobrutinib Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma NCT07030400n/a1 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424Phase 131 sites📍 Rochester📍 New York📍 Columbus Hoffmann-La Roche · Tests: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL NCT05702853Phase 1, Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06544785Phase 219 sites📍 Alicante📍 Barcelona📍 Barcelona PETHEMA Foundation · Tests: Zanubrutinib Oral Product, Obinutuzumab Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma NCT06916767Phase 11 site📍 Cleveland Paolo Caimi, MD · Tests: BAFF CAR-T, Obinutuzumab, Cyclophosphamide, Fludarabine Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467Phase 211 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG2575 A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies NCT06708897Phase 15 sites📍 Louisville📍 Chapel Hill📍 Cincinnati Lomond Therapeutics Holdings, Inc. · Tests: Lonitoclax (ZE50-0134) Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762Phase 11 site📍 San Francisco C. Babis Andreadis · Tests: Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT04169737Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Acalabrutinib, Obinutuzumab, Venetoclax Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT03516617Phase 23 sites📍 Scottsdale📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) NCT06539182Phase 217 sites📍 Hefei📍 Beijing📍 Beijing Dizal Pharmaceuticals · Tests: DZD8586, DZD8586, DZD8586 A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL NCT07609823Phase 21 site📍 Nanjing Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363Phase 113 sites📍 Orange📍 Miami Beach📍 Tampa Carna Biosciences, Inc. · Tests: Docirbrutinib A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872Phase 3195 sites📍 Laguna Hills📍 Orange📍 Palo Alto BeOne Medicines · Tests: Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi NCT06466122Phase 21 site📍 Columbus Kerry Rogers · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Pirtobrutinib Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL NCT05694312Phase 23 sites📍 Florence📍 Novara📍 Torino Gruppo Italiano Malattie EMatologiche dell'Adulto · Tests: Ibrutinib 420 mg
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy